Latest Insights - page 67 | BiopharmaTrend

Nabla Bio Advances Generative Protein Design with $26M Series A Funding

Nabla Bio, a biotechnology firm specializing in generative protein design, has successfully closed a $26 million Series A financing round, led by Radical Ventures. The company also announced significant collaborations …

Continue ›››

Recursion Unveils BioHive-2, Fastest Pharma-Owned Supercomputer

Recursion Pharmaceuticals has achieved a significant milestone by completing BioHive-2, reportedly the fastest supercomputer to be wholly owned and operated by a pharmaceutical company. Developed in collaboration with Nvidia, BioHive-2 …

Continue ›››

Troubling Safety Data Overshadows Efficacy in MacroGenics' Phase 2 Study

MacroGenics, a biotechnology company, has reported concerning safety outcomes in its phase 2 trial of vobramitamab duocarmazine, a B7-H3-directed antibody-drug conjugate (ADC) aimed at treating metastatic castration-resistant prostate cancer. This …

Continue ›››

4 Biotech Startups Developing Breakthrough Drug Modalities

In the dynamic world of drug discovery, companies must continually innovate beyond their existing drug portfolios and modalities. Relying solely on familiar modalities limits the potential to develop more effective …

Continue ›››

DeepMind Launches Advanced AlphaFold Model to Enhance Drug Discovery

Google DeepMind has introduced the latest version of its AlphaFold artificial intelligence model, which aims to assist scientists in designing drugs and targeting diseases more effectively. This third iteration of …

Continue ›››

The Growing Impact of AI in Healthcare

The advent of artificial intelligence (AI) in healthcare has catalyzed an epoch of change, reshaping diagnostic procedures, therapeutic strategies, and patient monitoring processes, as well as the very ability to …

Continue ›››

Cytomos to Unveil Celledonia™ Technology at London Biotechnology Show 2024

Cytomos, a TechBio company, is gearing up to introduce attendees at the London Biotechnology Show 2024 to its latest development, Celledonia™, which is built upon the company's innovative AuraCyt™ platform. …

Continue ›››

Insilico Medicine Relocates Headquarters to Cambridge, Massachusetts

Insilico Medicine, a clinical-stage company specializing in AI-driven drug discovery, has shifted its corporate headquarters from New York to Boston. The company will maintain an office in New York but …

Continue ›››

From Diagnosis to Treatment: The Impact of AI on Rare Disease Drug Development

Drug development for rare (also referred to as orphan) diseases is notoriously challenging. Legislative initiatives, such as the 1983 US Orphan Drug Act and 1999 EU Orphan Regulation, provide regulatory …

Continue ›››

Optimising Drug Discovery R&D with Graphs

Data in Life Sciences expert Dr Alexander Jarasch on a new wave of advanced data handling techniques that point the way to new drug discovery breakthroughs Notoriously, drug discovery is …

Continue ›››

Cracking the Code of Life: An Interview with Stef van Grieken, CEO of Cradle, on AI-Driven Protein Engineering

The integration of artificial intelligence (AI) in biotech is not just enhancing the efficiency of processes but is also enabling the discovery of novel biological insights that were once beyond …

Continue ›››

Xaira Therapeutics Launches with Over $1 Billion to Enhance Drug R&D Using AI

As first reported by Endpoints News, Xaira Therapeutics has emerged as one of the most significantly funded new entrants in the biotech sector, supported by a consortium of venture capitalists …

Continue ›››